Literature DB >> 33599832

Serotype Distribution and Characteristics of the Minimum Inhibitory Concentrations of Streptococcus pneumoniae Isolated from Pediatric Patients in Kunming, China.

Mingbiao Ma1,2, Mei Yuan1, Ming Li3, Xiaojuan Li1, Hailin Huang1, Haiping Wang1, Jue Li1, Tingyi Du4,5, Rongwei Huang6.   

Abstract

Streptococcus pneumoniae (S. pneumoniae) is the main conditional pathogen of acute respiratory infection in infants, children, and older adults worldwide. It was great significant to identify the epidemic characteristics of serotypes and antibiotic susceptibility for the prevention and treatment of S. pneumoniae diseases. This research assessed the serotype distribution and the minimum inhibitory concentrations (MICs) of S. pneumoniae isolated from pediatric patients to provide information on the epidemiology and antibiotic resistance of S. pneumoniae in Kunming, China. A total of 140 S. pneumoniae isolates were collected from pediatric patients at Kunming Children's Hospital from January 2016 to October 2017. Serotype identification was done by Quellung reaction and multiplex polymerase chain reaction. MICs were determined by E-test. 140 isolates distributed in 13 types of serotypes. The top-three prevalent serotypes were 19F, 19A, and 6B. The immunization coverage rate of 13-valent pneumococcal conjugate vaccine (PCV) was relatively higher and should be introduced into the vaccination program in the region. MIC50 of penicillin, ceftriaxone, and levofloxacin was 1 μg/mL. MIC50 for meropenem and vancomycin was 0.38 μg/mL. MIC90 of penicillin, ceftriaxone, and levofloxacin was 1.5 μg/mL and that of meropenem and vancomycin was 0.5 μg/mL. The MIC90 of erythromycin was > 256 μg/mL. In summary, S. pneumoniae had low resistance rates to penicillin, ceftriaxone, levofloxacin, vancomycin, and meropenem, and these antibiotics could be the first-line agents for children with pneumococcal infections in Kunming.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33599832      PMCID: PMC7952279          DOI: 10.1007/s00284-021-02365-4

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  20 in total

1.  Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010.

Authors:  Lin Zhou; Sang-jie Yu; Wei Gao; Kai-hu Yao; A-dong Shen; Yong-hong Yang
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates.

Authors:  Rekha Pai; Robert E Gertz; Bernard Beall
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

3.  Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Authors:  Walter H B Demczuk; Irene Martin; Averil Griffith; Brigitte Lefebvre; Allison McGeer; Marguerite Lovgren; Gregory J Tyrrell; Shalini Desai; Lindsey Sherrard; Heather Adam; Matthew Gilmour; George G Zhanel
Journal:  Can J Microbiol       Date:  2013-10-21       Impact factor: 2.419

Review 4.  Epidemiological differences among pneumococcal serotypes.

Authors:  William P Hausdorff; Daniel R Feikin; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2005-02       Impact factor: 25.071

Review 5.  Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.

Authors:  Hope L Johnson; Maria Deloria-Knoll; Orin S Levine; Sonia K Stoszek; Laura Freimanis Hance; Richard Reithinger; Larry R Muenz; Katherine L O'Brien
Journal:  PLoS Med       Date:  2010-10-05       Impact factor: 11.069

6.  Distribution of serotypes and antibiotic resistance of invasive pneumococcal disease isolates among children aged 5 years and under in Saudi Arabia (2000-2004).

Authors:  A M Shibl
Journal:  Clin Microbiol Infect       Date:  2008-09       Impact factor: 8.067

Review 7.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

Authors:  Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian
Journal:  Lancet       Date:  2009-09-12       Impact factor: 79.321

8.  Molecular characterization and antimicrobial susceptibility of Streptococcus pneumoniae isolated from children hospitalized with respiratory infections in Suzhou, China.

Authors:  Qian Geng; Tao Zhang; Yunfang Ding; Yunzhen Tao; Yuzun Lin; Yunzhong Wang; Steven Black; Genming Zhao
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

9.  Penicillin-Binding Protein Transpeptidase Signatures for Tracking and Predicting β-Lactam Resistance Levels in Streptococcus pneumoniae.

Authors:  Yuan Li; Benjamin J Metcalf; Sopio Chochua; Zhongya Li; Robert E Gertz; Hollis Walker; Paulina A Hawkins; Theresa Tran; Cynthia G Whitney; Lesley McGee; Bernard W Beall
Journal:  mBio       Date:  2016-06-14       Impact factor: 7.867

10.  Serotype prevalence and antibiotic susceptibility patterns of pneumococcal isolates in Zunyi city, China.

Authors:  Meijing Shen; Run Yao; Huan Yue; Jingzhi Zhang; Min Chen; Weiwei Zhang; Daishun Liu; Kaifeng Wu
Journal:  Saudi Med J       Date:  2017-12       Impact factor: 1.484

View more
  2 in total

1.  Comparative Genomic Analysis of Streptococcus pneumoniae Strains: Penicillin Non-susceptible Multi-drug-Resistant Serotype 19A Isolates.

Authors:  Lifeng Li; Juanjuan Zhou; Mingchao Li; Zengyuan Yu; Kaijie Gao; Junwen Yang; Ping Cheng; Junmei Yang; Wancun Zhang; Zhidan Yu; Huiqing Sun
Journal:  Curr Microbiol       Date:  2022-01-04       Impact factor: 2.188

2.  Molecular Characterization of Predominant Serotypes, Drug Resistance, and Virulence Genes of Streptococcus pneumoniae Isolates From East China.

Authors:  Li-Dan Huang; Mei-Juan Yang; Yan-Ying Huang; Ke-Yi Jiang; Jie Yan; Ai-Hua Sun
Journal:  Front Microbiol       Date:  2022-06-01       Impact factor: 6.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.